3 completed, 2 recruiting, 1 unknown, 1 withdrawn. 7 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Completed 3, Recruiting 2, Unknown 1, Withdrawn 1 |
| Phase 2 | 1 | Withdrawn 1 |
Follow Uncontrolled Hypertension: new trials by email Literature Review of Uncontrolled Hypertension trials Research Report on Uncontrolled Hypertension
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase IIIb Study to Investigate the Effect of Baxdrostat in Chinese Participants With Uncontrolled Hypertension. baxdrostat 2mg, Placebo 2mg - Uncontrolled Hypertension | Phase 3 | Recruiting | AstraZeneca | 286 | 2026-09-17 | 2026-10-15 |
| A Study to Evaluate the Efficacy and Safety in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension SAL0120, Placebo - Uncontrolled Hypertension, Resistant Hypertension | Phase 3 | Completed | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 256 | 2024-10-29 | 2026-08-27 |
| A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension Baxdrostat, Placebo - Uncontrolled Hypertension, Resistant Hypertension | Phase 3 | Completed | AstraZeneca | 326 | 2024-04-08 | 2026-04-21 |
| A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension Baxdrostat, Placebo - Uncontrolled Hypertension, Resistant Hypertension | Phase 3 | Completed | AstraZeneca | 796 | 2023-11-22 | 2026-11-03 |
| Intensification of Blood Pressure Lowering Therapeutics Based on Diuretics Versus Usual Management for Uncontrolled Hypertension IN Patients With Moderate to Severe Chronic Kidney Disease Antihypertensive algorithm, Standard of care - Chronic Kidney Disease(CKD), Uncontrolled Hypertension | Phase 3 | Recruiting | University Hospital, Tours | 720 | 2023-03-28 | 2026-08-03 |
| Adrenal Artery Ablation for Uncontrolled Hypertension Selective endovascular chemical ablation of adrenal gland, Traditional triple antihypertensive treatment - Uncontrolled Hypertension | Phase 3 | Unknown | Third Military Medical University | 40 | 2018-08-01 | 2018-09-06 |
| Rapid Renal Sympathetic Denervation for Resistant Hypertension II Renal Denervation (OneShot™ Renal Denervation System) - Resistant Hypertension, Uncontrolled Hypertension | Phase 2 / Phase 3 | Withdrawn | Medtronic Endovascular | 2013-09-01 | 2015-08-18 |
Hypertension (2) · Renal Insufficiency, Chronic (1)
Cardiovascular Diseases (2) · Vascular Diseases (2) · Chronic Disease (1) · Disease Attributes (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Kidney Diseases (1) · Male Urogenital Diseases (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Renal Insufficiency (1) · Urogenital Diseases (1) · Urologic Diseases (1)
Standard of Care (1)
AstraZeneca (3) · Medtronic Endovascular (1) · Shenzhen Salubris Pharmaceuticals Co., Ltd. (1) · Third Military Medical University (1) · University Hospital, Tours (1)
China (4) · Argentina (2) · Australia (2) · France (2) · India (2) · Italy (2) · Japan (2) · South Korea (2) · Turkey (Türkiye) (2) · Vietnam (2) · Austria (1) · Belgium (1) · Bulgaria (1) · Canada (1) · Czechia (1)
Dierk Scheinert, MD (1) · Guiseppe Mancia, MD (1)
PMID 40850955, PMID 39138914, PMID 40888730, PMID 42754276
2023 (1)